Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + bortezomib + lenalidomide with minimal dexamethasone for transplant-ineligible newly diagnosed multiple myeloma
2020-004425-23Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Oslo University Hospital. Primary endpoint: MRD negativity. Started Dec 2020; status: active.
02
Drugs
isatuximabbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-004425-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004425-23.